VacV Biotherapeutics

VacV Biotherapeutics is a cancer immunotherapy company developing engineered oncolytic Vaccinia virus-based therapeutics for the treatment of solid tumours.

Spun out of Barts Cancer Institute and Queen Mary University of London, the company's platform uses a modified Vaccinia virus to simultaneously destroy tumour cells and stimulate a durable anti-tumour immune response.

Its pipeline is in preclinical development, with lead programmes targeting pancreatic ductal adenocarcinoma, glioblastoma, and metastatic colorectal cancer.